0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Respiratory Drugs Pipeline Analysis Market 2018
Published Date: April 2019
|
Report Code: INFO-Othe-046
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global Respiratory Drugs Pipeline Analysis Market 2018

Global Respiratory Drugs Pipeline Analysis Market 2018

Code: INFO-Othe-046
Report
April 2019
188 Pages
Infoholic Research
Region: Global,
Description
Table of Content
Tables & Figures

Respiratory Drugs Pipeline Analysis
Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.
Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory dugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.
Industry Trends
• GSK’s Adavir for Asthma and COPD remains as the top selling drug in the market, even on declined revenue in 2017
• Pharmaceutical companies in US are facing pricing pressure and launch of new respiratory drugs in the market are declining the sales of the blockbuster drugs in the market
• Cipla Ltd., a leader in the Indian market, announced in May 2017, that it planned to reduce the investment on the biosimilars, to increase their focus on the respiratory drugs due to the high profitability
More than 30 companies pipeline for the respiratory drugs is analyzed in the study. GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.
Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.


Table of Contents


1 Industry Outlook 12
1.1 Industry Overview 12
1.1.1 Global Driver for Pharmaceutical Demand: 13
1.1.2 Pharmaceutical spending region wise 13
1.1.3 R&D pipeline in pharmaceutical industry 13
1.1.4 Top pharma drugs by sales in 2017 ($Million) 15
1.2 Industry Trends 17
1.3 Pest Analysis 17
2 Report Outline 19
2.1 Report Scope 19
2.2 Report Summary 19
2.3 Research Methodology 19
2.4 Report Assumptions 20
3 Market Snapshot 21
3.1 Market Definition – Infoholic Research 21
3.2 Segment Addressable Market 21
3.1 Trends of Respiratory Drugs Market 21
4 Molecule Type: Analysis 23
4.1 Overview 23
5 Application: Analysis 25
5.1 Overview 25
5.2 Asthma 25
5.2.1 Key Takeaways 30
5.2.2 Company Analysis 31
5.3 Chronic Obstructive Pulmonary Disease (COPD) 31
5.3.1 Key Takeaways 35
5.3.2 Company Analysis 36
5.4 Cystic Fibrosis 36
5.4.1 Key Takeaways 40
5.4.2 Company Analysis 40
5.5 Lung Cancer 40
5.5.1 Key Takeaways 45
5.5.2 Company Analysis 46
5.6 Nasal Polyps 46
5.6.1 Key Takeaways 47
5.7 Idiopathic Pulmonary Fibrosis 48
5.7.1 Key Takeaways 50
5.7.2 Company Analysis 50
5.8 Others 51
6 Competitive Landscape 52
6.1.1 Company Analysis 53
7 Vendors Profile 55
7.1 AbbVie Inc. 55
7.1.1 Overview 55
7.1.2 Geographic Presence 58
7.1.3 Business Focus 58
7.1.4 SWOT Analysis 59
7.1.5 Business Strategies 59
7.2 Amgen Inc. 60
7.2.1 Overview 60
7.2.2 Geographic Presence 63
7.2.3 Business Focus 64
7.2.4 SWOT Analysis 65
7.2.5 Business Strategies 67
7.3 Astra Zeneca PLC 67
7.3.1 Overview 67
7.3.2 Geographic Presence 71
7.3.3 Business Focus 71
7.3.4 SWOT Analysis 72
7.3.5 Business Strategy 72
7.4 Bayer AG 73
7.4.1 Overview 73
7.4.2 Business Unit 74
7.4.3 Geographic Presence 75
7.4.4 Business Focus 76
7.4.5 SWOT Analysis 76
7.4.6 Business Strategy 77
7.5 Boehringer Ingelheim GmbH 77
7.5.1 Overview 77
7.5.2 Geographic Presence 81
7.5.3 Business Focus 81
7.5.4 SWOT Analysis 81
7.5.5 Business Strategy 82
7.6 Bristol-Myers Squibb 83
7.6.1 Overview 83
7.6.2 Geographic Presence 87
7.6.3 Business Focus 87
7.6.4 SWOT Analysis 87
7.6.5 Business Strategy 88
7.7 Celgene Corporation 89
7.7.1 Overview 89
7.7.2 Geographic Presence 90
7.7.3 Business Focus 91
7.7.4 SWOT Analysis 91
7.7.5 Business Strategy 92
7.8 Dr. Reddy’s Laboratories Limited 93
7.8.1 Overview 93
7.8.2 Business Unit 97
7.8.3 Geographic Presence 99
7.8.4 Business Focus 99
7.8.5 SWOT Analysis 100
7.8.6 Business Strategy 100
7.9 Eli Lilly & Company Ltd 101
7.9.1 Overview 101
7.9.2 Business Focus 103
7.9.3 SWOT Analysis 104
7.9.4 Business Strategies 104
7.10 F.Hoffmann-La Roche Ltd. 105
7.10.1 Overview 105
7.10.2 Business Unit 108
7.10.3 Geographic Presence 109
7.10.4 Business Focus 109
7.10.5 SWOT Analysis 110
7.10.6 Business Strategy 110
7.11 GlaxoSmithKline plc 111
7.11.1 Overview 111
7.11.2 Geographic Presence 115
7.11.3 Business Focus 115
7.11.4 SWOT Analysis 116
7.11.5 Business Strategy 116
7.12 Johnson & Johnson 117
7.12.1 Overview 117
7.12.2 Business Units 120
7.12.3 Geographic Revenue 121
7.12.4 Business Focus 122
7.12.5 SWOT Analysis 123
7.12.6 Business Strategies 123
7.13 Merck & Co., Inc. 124
7.13.1 Overview 124
7.13.2 Business units 126
7.13.3 Geographic Revenue 127
7.13.4 Business focus 128
7.13.5 SWOT analysis 128
7.13.6 Business strategies 129
7.14 Mylan N.V. 129
7.14.1 Overview 129
7.14.2 Geographic Presence 133
7.14.3 Business Focus 133
7.14.4 SWOT Analysis 134
7.14.5 Business Strategy 134
7.15 Novartis AG 134
7.15.1 Overview 134
7.15.2 Business Unit 136
7.15.3 Geographic Presence 137
7.15.4 Business Focus 138
7.15.5 SWOT Analysis 138
7.15.6 Business Strategy 139
7.16 Pfizer, Inc., 140
7.16.1 Overview 140
7.16.2 Business Units 143
7.16.3 Geographic Presence 143
7.16.4 Business Focus 144
7.16.5 SWOT Analysis 144
7.16.6 Business Strategies 144
7.17 Sanofi 145
7.17.1 Overview 145
7.17.2 Geographic Presence 148
7.17.3 Business Focus 148
7.17.4 SWOT Analysis 148
7.17.5 Business Strategy 149
7.18 Teva Pharmaceutical Industries Ltd. 149
7.18.1 Overview 149
7.18.2 Business Unit 152
7.18.3 Geographic Presence 152
7.18.4 Business focus 153
7.18.5 SWOT analysis 153
7.18.6 Business Strategy 154
7.19 Vertex Pharmaceuticals Inc. 155
7.19.1 Overview 155
7.19.2 Geographic Presence 158
7.19.3 Business Focus 158
7.19.4 SWOT Analysis 159
7.19.5 Business Strategy 159
8 Companies to Watch For 160
8.1 FibroGen, Inc 160
8.1.1 Overview 160
8.1.2 Highlights 160
8.2 Gilead Sciences Inc. 161
8.2.1 Overview 161
8.2.2 Highlights: 162
8.3 Glenmark Pharmaceutical Ltd 163
8.3.1 Overview 163
8.4 Zia Labs 164
8.4.1 Overview 164
8.4.2 Zia Lab: Highlights 164
8.5 Vectura Group Plc 165
8.5.1 Overview 165
8.5.2 Vectura Group Plc: Highlights 166
8.6 Sosei Group Corporation 166
8.6.1 Overview 166
8.7 Almirall S.A. 167
8.7.1 Overview 167
8.8 Biogen Inc 168
8.8.1 Overview 168
8.9 CHIESI Farmaceutici SpA 169
8.9.1 Overview 169
8.9.2 CHIESI Farmaceutici SpA: Highlights 170
8.10 Takeda Pharmaceutical Co, Ltd 170
8.10.1 Overview 170
8.10.2 Highlights 171
8.11 Shionogi & Co., Ltd 171
8.11.1 Overview 171
8.11.2 Shionogi & Co., Ltd: Highlights 172
8.12 Sun Pharmaceuticals 172
8.12.1 Overview 172
8.12.2 Highlights 173
8.13 United Therapeutics Corp 173
8.13.1 Overview 173
8.13.2 Highlights 174
8.14 ProMetic Life Sciences Inc. 174
8.14.1 Overview 174
8.14.2 ProMetic Life Sciences Inc.: Highlights 175
8.15 Daiichi Sankyo, Inc. 175
8.15.1 Overview 175
8.15.2 Overview 176
8.16 Aurobindo Pharma Ltd 176
8.16.1 Overview 176
8.16.2 Aurobindo Pharma Ltd: Highlights 177
8.17 Eisai Co., Ltd 177
8.17.1 Overview 177
8.17.2 Eisai Co., Ltd: Highlights 178
8.18 Shire Plc 179
8.18.1 Overview 179
8.18.2 Shire Plc: Highlights 181
8.19 GNI Group Ltd 181
8.19.1 Overview 181
8.20 MediciNova, Inc 182
8.20.1 Overview 182
8.21 Ono Pharmaceutical Co., Ltd 182
8.21.1 Overview 182
8.22 Promedior, Inc 183
8.22.1 Overview 183
8.23 Sumitomo Dainippon Pharma Co., Ltd. 184
8.23.1 Overview 184
8.23.2 Sumitomo Dainippon Pharma Co., Ltd: Highlights 185
9 Annexure 186
Abbreviations 186

List of Tables

TABLE 1 MOLECULES IN PIPELINE FOR ASTHMA 27
TABLE 2 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 33
TABLE 3 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 37
TABLE 4 MOLECULES IN PIPELINE FOR LUNG CANCER 42
TABLE 5 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 47
TABLE 6 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 49
TABLE 7 ABBVIE INC.: OFFERINGS 56
TABLE 8 ABBVIE INC: RECENT DEVELOPMENTS 56
TABLE 9 AMGEN INC.: OFFERINGS 61
TABLE 10 AMGEN INC.: RECENT DEVELOPMENTS 61
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 68
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 69
TABLE 13 BAYER AG: OFFERINGS 74
TABLE 14 BAYER AG: RECENT DEVELOPMENTS 74
TABLE 15 BOEHRINGER INGELHEIM GMBH: OFFERINGS 79
TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 79
TABLE 17 BRISTOL-MYERS SQUIBB: OFFERINGS 84
TABLE 18 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 84
TABLE 19 CELGENE CORPORATION: OFFERINGS 90
TABLE 20 CELGENE CORPORATION: RECENT DEVELOPMENTS 90
TABLE 21 DR. REDDY’S LABORATORIES LIMITED: PRODUCT OFFERINGS 94
TABLE 22 DR. REDDY’S LABORATORIES LIMITED: RECENT DEVELOPMENTS 94
TABLE 23 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 102
TABLE 24 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 102
TABLE 25 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 106
TABLE 26 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 107
TABLE 27 GLAXOSMITHKLINE PLC: OFFERINGS 112
TABLE 28 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 113
TABLE 29 JOHNSON & JOHNSON: PRODUCT OFFERINGS 118
TABLE 30 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 118
TABLE 31 MERCK & CO: PRODUCT OFFERINGS 125
TABLE 32 MERCK & CO: RECENT DEVELOPMENTS 125
TABLE 33 MYLAN N.V.: OFFERINGS 131
TABLE 34 MYLAN N.V.: RECENT DEVELOPMENT 131
TABLE 35 NOVARTIS AG: OFFERINGS 136
TABLE 36 NOVARTIS AG: RECENT DEVELOPMENTS 136
TABLE 37 PFIZER, INC.: OFFERINGS 141
TABLE 38 PFIZER, INC.: RECENT DEVELOPMENTS 142
TABLE 39 SANOFI: OFFERINGS 146
TABLE 40 SANOFI: RECENT DEVELOPMENTS 146
TABLE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 151
TABLE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 151
TABLE 43 VERTEX PHARMACEUTICALS INC.: OFFERINGS 156
TABLE 44 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS 156
TABLE 45 FIBROGEN, INC: OVERVIEW 161
TABLE 46 FIBROGEN INC: RECENT DEVELOPMENTS 161
TABLE 47 GILEAD SCIENCES INC.: OVERVIEW 162
TABLE 48 GILEAD SCIENCE INC: RECENT DEVELOPMENTS 162
TABLE 49 GLENMARK PHARMACEUTICAL LTD: OVERVIEW 164
TABLE 50 GLENMARK PHARMACEUTICAL LTD: RECENT DEVELOPMENTS 164
TABLE 51 ZIA LAB: OVERVIEW 165
TABLE 52 ZIA LAB: RECENT DEVELOPMENTS 165
TABLE 53 VECTURA GROUP PLC: OVERVIEW 166
TABLE 54 VECTURA GROUP AG: RECENT DEVELOPMENTS 166
TABLE 55 SOSEI GROUP CORPORATION: OVERVIEW 167
TABLE 56 SOSEI GROUP CORPORATION: RECENT DEVELOPMENTS 167
TABLE 57 ALMIRALL S.A: OVERVIEW 168
TABLE 58 ALMIRALL S.A.: RECENT DEVELOPMENTS 169
TABLE 59 BIOGEN INC: OVERVIEW 169
TABLE 60 BIOGEN INC: RECENT DEVELOPMENTS 170
TABLE 61 CHIESI FARMACEUTICI SPA: OVERVIEW 170
TABLE 62 CHIESI FARMACEUTICI SPA: RECENT DEVELOPMENTS 170
TABLE 63 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW 171
TABLE 64 TAKEDA PHARMACEUTICAL CO, LTD: RECENT DEVELOPMENTS 171
TABLE 65 SHIONOGI & CO., LTD: OVERVIEW 172
TABLE 66 SHIONOGI & CO., LTD: RECENT DEVELOPMENTS 172
TABLE 67 SUN PHARMACEUTICALS: OVERVIEW 173
TABLE 68 ZIA LAB: RECENT DEVELOPMENTS 174
TABLE 69 UNITED THERAPEUTICS CORP.: OVERVIEW 174
TABLE 70 PROMETIC LIFE SCIENCES INC.: OVERVIEW 175
TABLE 71 PROMETIC LIFE SCIENCES INC.: RECENT DEVELOPMENTS 176
TABLE 72 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 176
TABLE 73 AUROBINDO PHARMA LTD: OVERVIEW 177
TABLE 74 AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS 177
TABLE 75 EISAI CO., LTD: OVERVIEW 179
TABLE 76 EISAI CO., LTD: RECENT DEVELOPMENTS 179
TABLE 77 SHIRE PLC: OVERVIEW 180
TABLE 78 SHIRE PLC: RECENT DEVELOPMENTS 180
TABLE 79 GNI GROUP LTD: OVERVIEW 182
TABLE 80 GNI GROUP LTD: RECENT DEVELOPMENTS 182
TABLE 81 MEDICINOVA INC: OVERVIEW 183
TABLE 82 MEDICINOVA INC: RECENT DEVELOPMENTS 183
TABLE 83 ONO PHARMACEUTICAL CO., LTD: OVERVIEW 184
TABLE 84 ONO PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS 184
TABLE 85 PROMEDIOR, INC: OVERVIEW 185
TABLE 86 PROMEDIOR INC: RECENT DEVELOPMENTS 185
TABLE 87 SUMITOMO DAINIPPON PHARMA CO., LTD: OVERVIEW 186
TABLE 88 SUMITOMO DAINIPPON PHARMA CO., LTD: RECENT DEVELOPMENTS 186

List of Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 16
CHART 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 17
CHART 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 18
CHART 4 PHARMACEUTICAL DRUGS BY SALES, 2017 19
CHART 5 PEST ANALYSIS OF RESPIRATORY DRUGS MARKET 20
CHART 6 RESEARCH METHODOLOGY OF RESPIRATORY DRUGS PIPELINE 22
CHART 7 NUMBER OF LARGE MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS 26
CHART 8 NUMBER OF SMALL MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS 26
CHART 9 RESPIRATORY PRODUCT PIPELINE BASED ON THE MOLECULE TYPE 27
CHART 1 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%) 28
CHART 2 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR ASTHMA 33
CHART 3 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 37
CHART 4 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 42
CHART 5 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER 48
CHART 6 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER 50
CHART 7 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR IDOPATHIC PULMONARY FIBROSIS 52
CHART 8 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR OTHER RESPIRATORY DISEASES 54
CHART 9 ABBVIEE INC: OVERVIEW SNAPSHOT 60
CHART 10 ABBVIEE INC.: GEOGRAPHIC PRESENCE 61
CHART 11 ABBVIE INC.: SWOT ANALYSIS 62
CHART 12 AMGEN INC.: OVERVIEW SNAPSHOT 65
CHART 13 AMGEN INC.: GEOGRAPHIC PRESENCE 66
CHART 14 AMGEN: SWOT ANALYSIS 68
CHART 15 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT 71
CHART 16 ASTRA ZENCA PLC: BUSINESS UNITS 73
CHART 17 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE 74
CHART 18 ASTRA ZENCA PLC: SWOT ANALYSIS 75
CHART 19 BAYER AG: OVERVIEW SNAPSHOT 77
CHART 20 BAYER AG: BUSINESS UNITS 77
CHART 21 BAYER GA: GEOGRAPHICAL PRESENCE 78
CHART 22 BAYER AG: SWOT ANALYSIS 79
CHART 23 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT 81
CHART 24 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS 82
CHART 25 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC PRESENCE 84
CHART 26 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS 84
CHART 27 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT 88
CHART 28 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS 89
CHART 29 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE 90
CHART 30 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS 90
CHART 31 CELGENE CORPORATION: OVERVIEW SNAPSHOT 93
CHART 32 CELGENE CORPORATION: GEOGRAPHIC PRESENCE 93
CHART 33 CELGENE CORPORATION: SWOT ANALYSIS 94
CHART 34 DR. REDDY’S LABORATORY LIMITED: OVERVIEW SNAPSHOT 100
CHART 35 DR. REDDY’S LABORATORY LIMITED: BUSINESS UNITS 100
CHART 36 DR. REDDY’S LABORATORY LIMITED: GEOGRAPHICAL PRESENCE 102
CHART 37 DR. REDDY’S LABORATORY LIMITED: SWOT ANALYSIS 103
CHART 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 105
CHART 39 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 105
CHART 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 106
CHART 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 107
CHART 42 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 108
CHART 43 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS 111
CHART 44 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 112
CHART 45 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 113
CHART 46 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 114
CHART 47 GLAXOSMITHKLINE PLC: BUSINESS UNITS 117
CHART 48 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 118
CHART 49 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 119
CHART 50 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 122
CHART 51 JOHNSON & JOHNSON: BUSINESS UNITS 123
CHART 52 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 124
CHART 53 JOHNSON & JOHNSON: SWOT ANALYSIS 126
CHART 54 MERCK & CO: OVERVIEW SNAPSHOT 128
CHART 55 MERCK & CO: BUSINESS UNITS 129
CHART 56 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 130
CHART 57 MERCK & CO: SWOT ANALYSIS 131
CHART 58 MYLAN N.V. OVERVIEW SNAPSHOT 134
CHART 59 MYLAN N.V..: BUSINESS SEGMENTS 134
CHART 60 MYLAN N.V..: GEOGRAPHIC PRESENCE 136
CHART 61 MYLAN N.V..: SWOT ANALYSIS 137
CHART 62 NOVARTIS AG: OVERVIEW SNAPSHOT 139
CHART 63 NOVARTIS AG: BUSINESS UNITS 139
CHART 64 NOVARTIS AG: GEOGRAPHICAL PRESENCE 140
CHART 65 NOVARTIS AG: SWOT ANALYSIS 141
CHART 66 PFIZER, INC.: OVERVIEW SNAPSHOT 145
CHART 67 PFIZER INC.: BUSINESS UNITS 146
CHART 68 PFIZER INC.: GEOGRAPHIC PRESENCE 146
CHART 69 PFIZER INC: SWOT ANALYSIS 147
CHART 70 SANOFI SA: OVERVIEW SNAPSHOT 149
CHART 71 SANOFI SA: SEGMENTATION 150
CHART 72 SANOFI SA: GEOGRAPHIC REVENUE 151
CHART 73 SANOFI SA: SWOT ANALYSIS 151
CHART 74 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 154
CHART 75 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 155
CHART 76 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE 155
CHART 77 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 156
CHART 78 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT 160
CHART 79 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE 161
CHART 80 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS 162

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3500
This license allows only one user to access the PDF.

Electronic (PDF)
$4000
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$4500
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
SecuX Technology Inc

RELATED REPORTS

Global and China Membrane Bioreactor MBR Systems Market Insights Forecast to 2027
Global and China Membrane Bioreactor (MBR) Systems Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-24N7565
Tue Nov 30 00:00:00 UTC 2021

Add to Cart

Global and China Oligonucleotide API Market Insights Forecast to 2027
Global and China Oligonucleotide API Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-34J7553
Tue Nov 30 00:00:00 UTC 2021

Add to Cart

Global and Japan Prokaryotic Recombinant Protein Market Insights Forecast to 2027
Global and Japan Prokaryotic Recombinant Protein Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-20U7714
Tue Nov 30 00:00:00 UTC 2021

Add to Cart

Global and China Lentiviral Vector In Gene Therapy Market Insights Forecast to 2027
Global and China Lentiviral Vector In Gene Therapy Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-30V7563
Tue Nov 30 00:00:00 UTC 2021

Add to Cart